![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CTSK |
Gene summary for CTSK |
![]() |
Gene information | Species | Human | Gene symbol | CTSK | Gene ID | 1513 |
Gene name | cathepsin K | |
Gene Alias | CTS02 | |
Cytomap | 1q21.3 | |
Gene Type | protein-coding | GO ID | GO:0000422 | UniProtAcc | P43235 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1513 | CTSK | AEH-subject1 | Human | Endometrium | AEH | 1.53e-26 | -5.77e-01 | -0.3059 |
1513 | CTSK | AEH-subject2 | Human | Endometrium | AEH | 2.35e-29 | -5.67e-01 | -0.2525 |
1513 | CTSK | AEH-subject3 | Human | Endometrium | AEH | 2.15e-19 | -5.64e-01 | -0.2576 |
1513 | CTSK | AEH-subject4 | Human | Endometrium | AEH | 5.39e-18 | -4.34e-01 | -0.2657 |
1513 | CTSK | AEH-subject5 | Human | Endometrium | AEH | 5.15e-28 | -6.29e-01 | -0.2953 |
1513 | CTSK | EEC-subject1 | Human | Endometrium | EEC | 5.49e-38 | -6.34e-01 | -0.2682 |
1513 | CTSK | EEC-subject2 | Human | Endometrium | EEC | 3.05e-34 | -6.32e-01 | -0.2607 |
1513 | CTSK | EEC-subject3 | Human | Endometrium | EEC | 6.59e-43 | -5.94e-01 | -0.2525 |
1513 | CTSK | EEC-subject4 | Human | Endometrium | EEC | 8.68e-31 | -5.78e-01 | -0.2571 |
1513 | CTSK | EEC-subject5 | Human | Endometrium | EEC | 2.35e-26 | -6.19e-01 | -0.249 |
1513 | CTSK | GSM5276934 | Human | Endometrium | EEC | 6.39e-13 | -4.76e-01 | -0.0913 |
1513 | CTSK | GSM5276935 | Human | Endometrium | EEC | 4.05e-26 | -6.11e-01 | -0.123 |
1513 | CTSK | GSM5276937 | Human | Endometrium | EEC | 8.90e-12 | -4.29e-01 | -0.0897 |
1513 | CTSK | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 7.26e-35 | -6.32e-01 | -0.1869 |
1513 | CTSK | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.53e-28 | -5.98e-01 | -0.1875 |
1513 | CTSK | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 6.46e-36 | -6.33e-01 | -0.1883 |
1513 | CTSK | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 2.75e-35 | -6.16e-01 | -0.1934 |
1513 | CTSK | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.45e-37 | -6.52e-01 | -0.1917 |
1513 | CTSK | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 4.27e-44 | -6.29e-01 | -0.1916 |
1513 | CTSK | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 2.14e-04 | -3.43e-01 | -0.1269 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004877111 | Skin | SCCIS | tissue remodeling | 19/919 | 175/18723 | 9.98e-04 | 1.25e-02 | 19 |
GO:00329632 | Skin | SCCIS | collagen metabolic process | 13/919 | 104/18723 | 1.72e-03 | 1.87e-02 | 13 |
GO:006024916 | Skin | SCCIS | anatomical structure homeostasis | 28/919 | 314/18723 | 1.74e-03 | 1.88e-02 | 28 |
GO:0046849 | Skin | SCCIS | bone remodeling | 11/919 | 90/18723 | 4.51e-03 | 3.78e-02 | 11 |
GO:005121611 | Skin | SCCIS | cartilage development | 18/919 | 190/18723 | 5.86e-03 | 4.52e-02 | 18 |
GO:006144811 | Skin | SCCIS | connective tissue development | 22/919 | 252/18723 | 6.57e-03 | 4.89e-02 | 22 |
GO:0022411112 | Skin | cSCC | cellular component disassembly | 201/4864 | 443/18723 | 4.09e-19 | 5.69e-17 | 201 |
GO:190300817 | Skin | cSCC | organelle disassembly | 65/4864 | 114/18723 | 2.03e-12 | 1.12e-10 | 65 |
GO:000042219 | Skin | cSCC | autophagy of mitochondrion | 44/4864 | 81/18723 | 5.28e-08 | 1.36e-06 | 44 |
GO:006172619 | Skin | cSCC | mitochondrion disassembly | 44/4864 | 81/18723 | 5.28e-08 | 1.36e-06 | 44 |
GO:00065758 | Skin | cSCC | cellular modified amino acid metabolic process | 73/4864 | 188/18723 | 7.11e-05 | 6.85e-04 | 73 |
GO:000150323 | Skin | cSCC | ossification | 137/4864 | 408/18723 | 3.39e-04 | 2.68e-03 | 137 |
GO:0022411113 | Thyroid | PTC | cellular component disassembly | 232/5968 | 443/18723 | 1.36e-19 | 1.75e-17 | 232 |
GO:190300818 | Thyroid | PTC | organelle disassembly | 73/5968 | 114/18723 | 1.60e-12 | 7.12e-11 | 73 |
GO:0000422110 | Thyroid | PTC | autophagy of mitochondrion | 55/5968 | 81/18723 | 2.95e-11 | 1.10e-09 | 55 |
GO:0061726110 | Thyroid | PTC | mitochondrion disassembly | 55/5968 | 81/18723 | 2.95e-11 | 1.10e-09 | 55 |
GO:0001503110 | Thyroid | PTC | ossification | 176/5968 | 408/18723 | 9.26e-07 | 1.40e-05 | 176 |
GO:000657513 | Thyroid | PTC | cellular modified amino acid metabolic process | 85/5968 | 188/18723 | 8.29e-05 | 7.01e-04 | 85 |
GO:00301986 | Thyroid | PTC | extracellular matrix organization | 124/5968 | 301/18723 | 3.75e-04 | 2.53e-03 | 124 |
GO:00430626 | Thyroid | PTC | extracellular structure organization | 124/5968 | 302/18723 | 4.38e-04 | 2.92e-03 | 124 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0532316 | Endometrium | AEH | Rheumatoid arthritis | 23/1197 | 93/8465 | 4.43e-03 | 2.46e-02 | 1.80e-02 | 23 |
hsa0421010 | Endometrium | AEH | Apoptosis | 30/1197 | 136/8465 | 7.72e-03 | 4.05e-02 | 2.96e-02 | 30 |
hsa0532317 | Endometrium | AEH | Rheumatoid arthritis | 23/1197 | 93/8465 | 4.43e-03 | 2.46e-02 | 1.80e-02 | 23 |
hsa0421015 | Endometrium | AEH | Apoptosis | 30/1197 | 136/8465 | 7.72e-03 | 4.05e-02 | 2.96e-02 | 30 |
hsa0532323 | Endometrium | EEC | Rheumatoid arthritis | 24/1237 | 93/8465 | 3.14e-03 | 1.78e-02 | 1.33e-02 | 24 |
hsa0421024 | Endometrium | EEC | Apoptosis | 31/1237 | 136/8465 | 6.72e-03 | 3.25e-02 | 2.42e-02 | 31 |
hsa0532333 | Endometrium | EEC | Rheumatoid arthritis | 24/1237 | 93/8465 | 3.14e-03 | 1.78e-02 | 1.33e-02 | 24 |
hsa0421034 | Endometrium | EEC | Apoptosis | 31/1237 | 136/8465 | 6.72e-03 | 3.25e-02 | 2.42e-02 | 31 |
hsa0414222 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa0421027 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa0532320 | Esophagus | ESCC | Rheumatoid arthritis | 59/4205 | 93/8465 | 4.98e-03 | 1.27e-02 | 6.52e-03 | 59 |
hsa0414232 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa0421037 | Esophagus | ESCC | Apoptosis | 102/4205 | 136/8465 | 1.05e-09 | 1.21e-08 | 6.21e-09 | 102 |
hsa05323110 | Esophagus | ESCC | Rheumatoid arthritis | 59/4205 | 93/8465 | 4.98e-03 | 1.27e-02 | 6.52e-03 | 59 |
hsa0421018 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
hsa041425 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa0532318 | Oral cavity | OSCC | Rheumatoid arthritis | 56/3704 | 93/8465 | 9.72e-04 | 2.76e-03 | 1.40e-03 | 56 |
hsa043806 | Oral cavity | OSCC | Osteoclast differentiation | 73/3704 | 128/8465 | 1.60e-03 | 4.44e-03 | 2.26e-03 | 73 |
hsa04620 | Oral cavity | OSCC | Toll-like receptor signaling pathway | 58/3704 | 104/8465 | 8.77e-03 | 1.98e-02 | 1.01e-02 | 58 |
hsa0421019 | Oral cavity | OSCC | Apoptosis | 101/3704 | 136/8465 | 3.34e-13 | 7.00e-12 | 3.56e-12 | 101 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTSK | deletion | Frame_Shift_Del | novel | c.981delC | p.Lys328ArgfsTer39 | p.K328Rfs*39 | P43235 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
CTSK | SNV | Missense_Mutation | c.676N>C | p.Glu226Gln | p.E226Q | P43235 | protein_coding | tolerated(0.12) | possibly_damaging(0.468) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
CTSK | SNV | Missense_Mutation | novel | c.152N>G | p.Glu51Gly | p.E51G | P43235 | protein_coding | deleterious(0.01) | benign(0.317) | TCGA-5M-AAT4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
CTSK | SNV | Missense_Mutation | novel | c.696G>T | p.Glu232Asp | p.E232D | P43235 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CTSK | SNV | Missense_Mutation | novel | c.484N>A | p.Leu162Met | p.L162M | P43235 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CTSK | SNV | Missense_Mutation | novel | c.320A>G | p.Tyr107Cys | p.Y107C | P43235 | protein_coding | deleterious(0.01) | possibly_damaging(0.656) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
CTSK | SNV | Missense_Mutation | c.380N>C | p.Val127Ala | p.V127A | P43235 | protein_coding | deleterious(0) | probably_damaging(0.918) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
CTSK | SNV | Missense_Mutation | novel | c.742N>A | p.Ala248Thr | p.A248T | P43235 | protein_coding | deleterious(0) | benign(0.052) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
CTSK | SNV | Missense_Mutation | c.369G>T | p.Lys123Asn | p.K123N | P43235 | protein_coding | deleterious(0.03) | probably_damaging(0.923) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
CTSK | SNV | Missense_Mutation | novel | c.847N>A | p.Tyr283Asn | p.Y283N | P43235 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | PMID25399719-Compound-17 | |||
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | inhibitor | ODANACATIB | ODANACATIB | |
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | ODANACATIB | ODANACATIB | ||
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | PMID27998201-Compound-10 | |||
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | MIV-701 | |||
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | inhibitor | 223366192 | RELACATIB | |
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | 2-(1-CYCLODODECYLETHYLIDENE)HYDRAZINECARBOTHIOAMIDE | CHEMBL2316602 | 23350811 | |
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | inhibitor | BALICATIB | BALICATIB | |
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | VEL-0230 | CHEMBL1085282 | ||
1513 | CTSK | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, PROTEASE, ENZYME | inhibitor | 252166814 |
Page: 1 2 3 |